PT - JOURNAL ARTICLE AU - Kitamura, Hiroko AU - Ishigaki, Yo AU - Ohashi, Hideaki AU - Yokogawa, Shinji TI - Workplace ventilation improvement to address coronavirus disease 2019 cluster occurrence in a manufacturing factory AID - 10.1101/2022.04.04.22271935 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.04.22271935 4099 - http://medrxiv.org/content/early/2022/04/05/2022.04.04.22271935.short 4100 - http://medrxiv.org/content/early/2022/04/05/2022.04.04.22271935.full AB - Aim and Methods A coronavirus disease 2019 (COVID-19) cluster emerged in a manufacturing factory in early August 2021. In November 2021, a ventilation survey using tracer gas and data analysis was performed to reproduce the situation at the time of cluster emergence and verify that ventilation in the office increased the risk of aerosol transmission; verify the effectiveness of measures implemented immediately in August; and verify the effectiveness of additional measures when previously enforced measures proved inadequate.Results At the time of cluster emergence, the average ventilation frequency was 0.73 times/h, less than the 2 times/h recommended by the Ministry of Health, Labour, and Welfare; as such, the factory’s situation was deemed to have increased the risk of aerosol transmission. Due to the measures already taken at the time of the survey, the ventilation frequency increased to 3.41 times/h on average. It was confirmed that ventilation frequency increased to 8.33 times/h on average, when additional measures were taken.Conclusion To prevent the re-emergence of COVID-19 clusters, it is necessary to continue the measures that have already been implemented. Additionally, introduction of real-time monitoring that visualizes CO2 concentrations is recommended. Furthermore, we believe it is helpful that external researchers in multiple fields and internal personnel in charge of health and safety department and occupational health work together to confirm the effectiveness of conducted measures, such as this case.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by JSPS KAKENHI Grant No. 21K19820.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the following ethics committee. The approval number is 21005. The official name and location of the committee is 'Ethics Committee on Experiments on Human Subjects, The University of Electro-communications, Chofugaoka 1-5-1, Chofu, Tokyo, Japan'. The members of the committee are as follows: <Members' Directory> Director Sadao Obana ; Professor Yutaka Kano, Chairman ; Professor Hiroyui Kajimoto, Deputy Chairperson ; Professor Akihiro Kashihara ; Professor Akira Orimo, M.D., External committee member, School of Medicine, Juntendo University ; Professor Takashi Yokoi, External committee member, Faculty of Human Sciences and Design, Japan Women's University ; Akio Hamani, Esq., External committee member, Corporation lawyer ; Accociate Professor Shinobu Tsurugano, M.D., Health Care Cener ; Accociate Professor Soichi Ando ; Accociate Professor Tetsuro Funato ; Accociate Professor Kazuyuki Mito ; Accociate Professor Guanghao Sun. All researchers at the University of Electro-Communications adhere to the Research Ethics Guidelines (ex. https://www.uec.ac.jp/about/activity/fraud_prevention/pdf/leaflet_e.pdf) and have submitted a written pledge (ex. https://www.uec.ac.jp/about/activity/fraud_prevention/pdf/seiyakusyo_e.pdf). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.